Department of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.
Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
J Gastroenterol Hepatol. 2023 Aug;38(8):1346-1354. doi: 10.1111/jgh.16209. Epub 2023 May 8.
Bifidobacterium breve was the first bacteria isolated in the feces of healthy infants and is a dominant species in the guts of breast-fed infants. Some strains of B. breve have been shown to be effective at relieving intestinal inflammation, but the modes of action have yet to be elucidated. In this study, we investigated the mechanisms of action of B. breve CBT BR3 isolated from South Korean infant feces in relieving colitis in vitro and in vivo.
Colitis was induced in mice with dextran sodium sulfate (DSS) and dinitrobenzene sulfonic acid (DNBS). Quantitative reverse-transcription polymerase chain reaction, in vitro FITC-dextran flux permeability assay, and aryl hydrocarbon receptor (AhR) luciferase assay are performed using Caco-2 cells and HT29-Lucia™ AhR cells.
B. breve CBT BR3 was orally administered. B. breve CBT BR3 improved colitis symptoms in both DSS- and DNBS-induced colitis models. B. breve CBT BR3 increased the number of goblet cells per crypt. B. breve increased the mRNA expressions of Notch, Spdef, Muc5, and Il22. The mRNA expressions of Occludin, which encodes a membrane tight-junction protein, and Foxo3, which encodes a protein related to butyrate metabolism, were also increased in the DSS- and DNBS-induced colitis models. B. breve CBT BR3 protected inflammation-induced epithelial cell permeability and improved goblet cell function by inducing aryl hydrocarbon receptor in vitro.
These results indicate that B. breve CBT BR3 is effective at relieving intestinal inflammation by augmenting goblet cell regeneration.
短双歧杆菌是从健康婴儿粪便中首次分离出来的细菌，是母乳喂养婴儿肠道中的优势物种。一些短双歧杆菌菌株已被证明能有效缓解肠道炎症，但作用机制尚不清楚。在本研究中，我们研究了从韩国婴儿粪便中分离出的短双歧杆菌 CBT BR3 在体外和体内缓解结肠炎的作用机制。
采用葡聚糖硫酸钠（DSS）和二硝基苯磺酸（DNBS）诱导小鼠结肠炎。使用 Caco-2 细胞和 HT29-Lucia™AhR 细胞进行定量逆转录聚合酶链反应、体外 FITC-葡聚糖通量渗透性测定和芳香烃受体（AhR）荧光素酶测定。
短双歧杆菌 CBT BR3 经口服给药。短双歧杆菌 CBT BR3 改善了 DSS 和 DNBS 诱导的结肠炎模型中的结肠炎症状。短双歧杆菌 CBT BR3 增加了每个隐窝的杯状细胞数量。短双歧杆菌增加了 Notch、Spdef、Muc5 和 Il22 的 mRNA 表达。Occludin（编码膜紧密连接蛋白的基因）和 Foxo3（编码与丁酸代谢有关的蛋白质的基因）的 mRNA 表达在 DSS 和 DNBS 诱导的结肠炎模型中也增加了。短双歧杆菌 CBT BR3 通过体外诱导芳香烃受体，保护炎症诱导的上皮细胞通透性并改善杯状细胞功能。
这些结果表明，短双歧杆菌 CBT BR3 通过增强杯状细胞再生来有效缓解肠道炎症。
